Amgen's Broad Portfolio Strength and Wide Moat Should Protect Profits Despite Upcoming Biosimilars
Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...
The Scientist20h
“Man on Fire” Syndrome, Ion Channels, and the Quest for Safer Pain Treatments
In 2004, a research group at Peking University First Hospital discovered a mutation in the gene coding for a sodium-channel ...